Features of the Clinic

Patient-Friendly Medical Care

"DC (Dendritic Cell Therapy)" → Treatment is possible with only 60–100cc of peripheral blood collection

Currently, DC therapy implemented at several facilities in Japan begins with the process of apheresis (a special component blood collection) to extract a type of cell called a monocyte.

However, since the number of monocytes within white blood cells is not particularly large to begin with, a temporary collection of a large volume of blood becomes necessary. This places a considerable burden on patients, and there are cases where patients must postpone DC treatment due to insufficient physical strength.

Furthermore, at the start of treatment — specifically at the point of apheresis — patients are faced with the extremely concerning issue of high medical costs, typically ranging from 2 to 2.5 million yen.

In contrast, our clinic adopts a peripheral blood approach (meaning standard blood collection from the arm), requiring only around 100cc of blood. This is followed by cultivation and administration to the patient. This method minimizes the physical burden on patients and, in terms of cost, enables treatment to be kept to a necessary minimum as indicated on a separate pricing page. We also implement a flexible pricing system that allows for reviewing and adjusting payments as treatment progresses.

Medical care that satisfies patients

"TIL (Tumor-Infiltrating Lymphocyte Therapy)" → Offers the best treatment options even for patients suffering from ascites

For patients suffering from ascites along with cancer progression, the blood components collected from the peritoneal (or pleural) fluid include their own valuable T lymphocytes. These lymphocytes are likely to be highly capable of recognizing cancer cell types specific to each individual patient, making it highly promising that they can precisely and directly target (pinpoint) the cancer cells.

Patient-Centered and Compassionate Care

"NK (Highly Activated Natural Killer Cell Therapy) / CAT (CD3-Activated Autologous Lymphocyte Therapy)" → We strive daily to administer cells in their most optimal condition

While the standard cultivation-to-infusion period is generally considered to be two weeks for CAT and three weeks for NK therapy, in practice, individual patients show variations in cell growth patterns and timeframes. For this reason, we prioritize administering the cells when they are in their best and most abundant state. Our cell culture specialists closely track and analyze each patient’s cellular development to ensure that the infusion is performed at the most optimal timing for that specific patient.